Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
547.36
-0.38 (-0.07%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
REGENERON PHARMACEUTICALS (NASDAQ:REGN) - A Potential Undervalued Biotech Stock
Today 6:30 EDT
REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector.
Via
Chartmill
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
July 03, 2025
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.
Via
Benzinga
Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps
July 02, 2025
While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory...
Via
Stocktwits
Topics
Death
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
July 02, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
July 01, 2025
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For July 01
July 01, 2025
Via
Benzinga
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
June 28, 2025
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Via
MarketBeat
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
June 26, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
1 Profitable Stock for Long-Term Investors and 2 to Question
June 26, 2025
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
Via
StockStory
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
June 25, 2025
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Via
Benzinga
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
June 24, 2025
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
June 22, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
June 20, 2025
Via
Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
June 20, 2025
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.
Via
Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
June 20, 2025
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.
Via
Stocktwits
Topics
Supply Chain
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
June 20, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss
June 18, 2025
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.
Via
Stocktwits
Topics
Death
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
June 18, 2025
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.
Via
Benzinga
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
June 15, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
June 15, 2025
These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching.
Via
The Motley Fool
Topics
Stocks
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
June 13, 2025
From
23andMe, Inc.
Via
GlobeNewswire
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
June 13, 2025
Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you.
Via
The Motley Fool
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
June 12, 2025
Via
The Motley Fool
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
June 11, 2025
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.
Via
Benzinga
Regeneron Pharma Shares Rise Over 3% After Key Signal
June 10, 2025
A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.
Via
Benzinga
Which S&P500 stocks are moving on Monday?
June 09, 2025
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Via
Chartmill
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
June 09, 2025
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
Via
Benzinga
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
June 07, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
June 05, 2025
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.
Via
Benzinga
23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer
June 05, 2025
Regeneron previously won 23andMe at auction. But now the company wants to reopen bidding with an offer from its former CEO.
Via
Investor's Business Daily
Topics
Bankruptcy
Lawsuit
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.